# Anti-amyloid medicines

Source: https://onco.cc/roadmaps/da-roadmap-anti-amyloid/  
OnCo record `da-roadmap-anti-amyloid` (Roadmap). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

From failed or withdrawn antibodies to two US-approved early-stage products, with access and ARIA still open.

## Summary

This roadmap is a teaching timeline for the Alzheimer’s antibody story on this atlas. It is not a prediction that more antibodies will help more stages.

## Fields

- Kind: Roadmap
- Last checked: 2026-09-21
- Tags: dementia-atlas

## Sources

- FDA Leqembi: https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval

## Connected records

- diagnoses: [Alzheimer’s disease](https://onco.cc/diagnoses/alzheimers-disease/)
- trials: [ENGAGE](https://onco.cc/trials/da-trial-engage/), [EXPEDITION 3](https://onco.cc/trials/da-trial-expedition3/)
- drugs: [Aducanumab](https://onco.cc/drugs/da-aducanumab/), [Donanemab](https://onco.cc/drugs/da-donanemab/), [Lecanemab](https://onco.cc/drugs/da-lecanemab/), [Remternetug](https://onco.cc/drugs/da-remternetug/)
- ideas: [Blood test before PET or lumbar puncture](https://onco.cc/ideas/da-idea-blood-first-triage/)

---
JSON: https://onco.cc/api/v1/entities/da-roadmap-anti-amyloid.json